QZQinxiang Zheng

Qinxiang Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinxiang Zheng has a total of 187 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Chen

    National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China

    13 shared publications
  • Xiaoyin Ma

    Laboratory of Developmental Cell Biology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, China; State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, 325003, China

    6 shared publications
  • Jiayao Feng

    Ningbo Eye Hospital, Wenzhou Medical University, Ningbo, China

    4 shared publications
  • Xingjie Zan

    Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou Key Laboratory of Perioperative Medicine, Wenzhou, Zhejiang, 325001, China

    4 shared publications
  • Zhenmin Le

    Ningde Municipal Hospital Ningde China

    4 shared publications
  • Chengjie Pan

    Ophthalmology Department, First Hospital of Jilin University, Changchun, Jilin Province, China

    3 shared publications

Latest Publications

  • Open Access

    MELAS Associated With a Large-Scale MT-ND2 Deletion

    by Weiwei Wang, Chenhui Mao, Hongdi Yuan, Qinxiang Zheng

    Introduction: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a clinically and genetically heterogeneous mitochondrial disorder. Although the m.3243A>G variant in MT-TL1 is the most common molecular cause, atypical cases with negative routine genetic testing and nondiagnostic muscle biopsy may pose a substantial diagnostic challenge. Here, we report a clinically diagnosed MELAS case with supportive neuropathological findings and a large-scale deletion involving MT-ND2. Case Report: A 20-year-old man presented with recurrent seizures and encephalopathic episodes over 1.5 years. His clinical course was characterized by episodic visual disturbance, hearing impairment, hemiparesis, and progressive encephalopathic deterioration. Serial magnetic resonance imaging revealed recurrent migratory cortical lesions involving the occipital, temporal, and frontal lobes, and magnetic resonance spectroscopy demonstrated a lactate peak. Cerebrospinal fluid analysis and autoimmune and infectious investigations were unremarkable. Electromyography, muscle biopsy, and initial next-generation sequencing, including testing for the common m.3243A>G variant, were nondiagnostic. Subsequent brain biopsy demonstrated laminar cortical necrosis, supporting a mitochondrial encephalopathic process. Multiplex ligation-dependent probe amplification further identified a large-scale pathogenic deletion involving MT-ND2. Based on the characteristic clinical course, neuroimaging pattern, neuropathological findings, and complementary genetic analysis, a diagnosis of MELAS was established. Conclusion: This case expands the diagnostic spectrum of MELAS and highlights that typical clinical and radiologic features may still be present even when routine lactate testing, muscle biopsy, and standard genetic screening are nondiagnostic. In highly suspected cases, brain biopsy and complementary methods for mitochondrial structural variation analysis, such as MLPA, may provide crucial diagnostic evidence.

  • Open Access

    Dual‐Dynamically Crosslinked Nanogels Enable Prolonged Ocular Retention for Multimodal Dry Eye Therapy

    by Yanru Xin, Sisi Chen, Shengli Huang, Mengqi Huang, Jingyan Zhu, Zijian Wang, Jianliang Shen, Qinxiang Zheng

    Dry eye disease (DED), a chronic disorder affecting nearly half the global population, is perpetuated by oxidative stress, inflammation, and tear film instability. Constrained by short precorneal residence and monotherapy, DED therapies necessitate frequent dosing and polypharmacy, leaving unmet needs for prolonged ocular retention and multimodal intervention. Herein, we develop berberine (BBR)‐loaded dual‐dynamically crosslinked nanogels (BBR@MPN‐NGs) integrating tannic acid (TA)‐zinc metal‐polyphenol networks with carboxymethyl chitosan/aldehyde‐functionalized poly(ethylene glycol) Schiff base networks, enabling a single‐platform multimodal therapy combining antioxidant, anti‐inflammatory, and lubricating capacities. Capitalizing on dual‐dynamic synergy, BBR@MPN‐NGs exhibit 1‐year colloidal and antioxidant stability alongside lubricity, while leveraging TA‐mediated adhesion and Schiff base reversibility to sustain corneal BBR exposure for 24 h, enabling once‐daily dosing. In murine DED models, BBR@MPN‐NGs outperform first‐line cyclosporine A and dexamethasone in promoting corneal epithelial repair and tear secretion. Mechanistically, the nanogels reprogram the pathological microenvironment by scavenging reactive oxygen species, attenuating pro‑inflammatory macrophage polarization, and suppressing c‐Jun N‐terminal kinase signaling to reduce pro‐inflammatory gene expression. Notably, the preservative‐free nanogels passed sterility and endotoxin testing, showing no ocular or systemic toxicity, which supports biosafety. These dual‐dynamically crosslinked nanogels enable reduced‐frequency and shortened treatment duration, offering an integrated strategy for complex ocular surface diseases requiring sustained multimodal intervention.

  • Open Access

    SIRT1 Prevents Ferroptosis in Corneal Epithelial Cells by Enhancing HIF1α Protein Stability in Dry Eye Disease

    by Lili Lian, Zhenmin Le, Xuanqiao Ye, Zimo Wang, Jiuxiao Li, Chenyu Dong, Yetao Shen, Jiazheng Li, Yueping Ren, Xiaoyin Ma, et al.

    Hyperosmotic stress induced by tear film instability significantly exacerbates oxidative damage in corneal epithelial cells, contributing to the pathogenesis of dry eye disease (DED). Ferroptosis, an iron‐dependent form of cell death driven by lipid peroxidation, has been identified as a critical downstream mechanism of oxidative damage in DED. However, its precise regulatory mechanisms remain unclear. In this study, we demonstrate that hyperosmotic stress promotes ferroptosis in corneal epithelial cells by downregulating the NAD‐dependent deacetylase sirtuin 1 (SIRT1). SIRT1 positively regulates GPX4, a pivotal mediator of ferroptosis. Pharmacological activation of SIRT1 using SRT1720 alleviated oxidative damage and suppressed ferroptosis in corneal epithelial cells both in vitro and in vivo. Mechanistically, we further observed that SIRT1 deacetylates the HIF1α, stabilizing it via the ubiquitin‐proteasome pathway. The SIRT1–HIF1α axis positively regulates GPX4 levels, thereby inhibiting ferroptosis activation. These results reveal a previously unrecognized pathway of ferroptosis regulation in DED and suggest a potential therapeutic strategy for reducing oxidative damage in corneal epithelium.


  • Open Access

    The Intracellular C5a–mtC5aR1 Axis Promotes Necroptosis in Dry Eye Through DRP1-Mediated Mitochondrial Dysfunction

    by Limei Wang, Haijing Yan, Yetao Shen, Songlin Xin, Chenyu Dong, Jiuxiao Li, Yueping Ren, Wei Chen, Qinxiang Zheng

    As a multifactorial ocular surface pathology, dry eye (DE) is marked by inflammation and epithelial damage. While mitochondrial dysfunction and oxidative stress are implicated, the mechanisms driving cornea epithelial cell damage remain unclear. This study investigates the role of C5a-mitochondrial C5a receptor 1 (mtC5aR1) in human corneal epithelial cells (HCECs) during DE pathogenesis. We examined C5aR1 expression and localization in HCECs under normal and hyperosmotic stress (mimicking DE) using molecular techniques. The functional role of the intracellular C5a-mtC5aR1 axis was assessed through pharmacological inhibition (JPE-1375 and PMX-53) and analysis of downstream signaling (RIPK3/MLKL-mediated necroptosis, DRP1 activation, mitochondrial function, and inflammatory cytokine production). The therapeutic potential of JPE-1375 was further evaluated in a DE mouse model, assessing corneal epithelial damage and inflammation. We demonstrate, for the first time, that HCECs express C5aR1 on the outer mitochondrial membrane (mtC5aR1), and its expression is upregulated in DE conditions. Hyperosmotic stress-induced local C5a production in HCECs activates mtC5aR1, triggering DRP1-mediated mitochondrial dysfunction and initiating RIPK3/MLKL-dependent necroptosis. Pharmacological blockade of mtC5aR1 with JPE-1375 significantly attenuated necroptosis, restored mitochondrial function, and reduced inflammatory cytokine production in stressed HCECs. Furthermore, JPE-1375 treatment mitigated corneal epithelial damage and inflammation in the DE mouse model. Our findings identify the intracellular C5a-mtC5aR1-DRP1 axis as a novel regulatory mechanism driving necroptosis in DE. Targeting this pathway represents a potential therapeutic approach to reduce inflammation and corneal damage in DE.


  • Open Access

    STING deficiency alleviates scar formation after glaucoma filtration surgery by suppressing p38 MAPK-induced inflammation in mice

    by Huifang Ye, Xinlei Lu, Hongjin Chen, Xi Yang, Han Xu, Lei Huang, Qinxiang Zheng, Rongrong Le, Yuanbo Liang

    Background: Glaucoma filtration surgery (GFS) often fails because of excessive scar formation driven by inflammation and fibroblast activation. Although the stimulator of interferon genes (STING) pathway is involved in inflammatory responses, its role in post-surgical fibrosis remains unclear. Methods: A mouse GFS model was established in wild-type (WT) and STING-knockout (STING-KO) animals. A parallel cohort of WT mice received a single intraoperative subconjunctival injection of the STING inhibitor H151. Bleb survival, intraocular pressure, histopathology, collagen deposition, and inflammatory/fibrotic markers were evaluated for 28 days. RNA sequencing, Western blotting, and ELISA were employed to profile the p38/MAPK axis. Primary human Tenon’s capsule fibroblasts were treated with angiotensin II in the presence or absence of STING silencing or H151 to corroborate mechanisms in vitro. Results: STING expression was markedly up-regulated in fibroblasts within human and mice post-GFS tissues. STING-KO mice exhibited prolonged bleb survival together with reduced collagen deposition and fibroblast activation. RNA-sequencing revealed that STING deletion significantly altered the p38 mitogen-activated protein kinase (MAPK) pathway. Mechanistically, STING deficiency suppressed p38 MAPK phosphorylation, leading to decreased levels of the pro-inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor-α, IL-18, and IL-1β, as well as the fibrogenic factors α-SMA, collagen I, fibronectin, connective tissue growth factor, and collagen type III alpha 1 at the surgical sites. Consistently, the selective STING inhibitor H151 recapitulated these effects by suppressing p38 MAPK signaling and markedly reducing fibrotic scarring. Conclusions: STING deficiency alleviates scar formation after GFS by suppressing p38 MAPK pathway. Targeting STING/p38 axis may improve surgical outcomes by modulating the balance between inflammation and tissue repair.

  • Open Access

    Real-World Safety Profile of EVO and EVO+ Implantable Collamer Lenses: A Retrospective Study Based on FDA Surveillance Data

    by Qing Chen, Shouxiang Ni, Haijing Yan, Qinxiang Zheng, Yueping Ren

    Introduction To evaluate and characterize adverse events (AEs) associated with EVO and EVO+ implantable collamer lens (ICL) using real-world post-marketing surveillance data from the Food and Drug Administration (FDA)'s MAUDE database. Methods A retrospective analysis was conducted on AE reports related to EVO and EVO+ ICLs, including both spherical and toric models, submitted between 2015 and 2023. After excluding duplicate entries and incomplete records, reports were stratified by lens model and optical type into four groups: spherical EVO, toric EVO, spherical EVO+, and toric EVO+. Each report was independently reviewed by two senior ophthalmologists to classify the associated complications. Descriptive statistics were used to evaluate the proportional distribution of complications across subgroups and to assess the annual trend in reported AEs. Results A total of 17,482 AEs reports were analyzed. Across all subgroups, over half of the reports documented no clinical signs or symptoms. Blurred vision was the most frequently reported visual complaint, with a relatively higher reporting frequency in the EVO+ groups. Events involving elevated intraocular pressure and glaucoma were more commonly reported among EVO+ recipients. In addition, a number of rare but clinically significant complications were documented, including hemorrhage, hyphema, decreased intraocular pressure, endophthalmitis, and toxic anterior segment syndrome. The annual number of reported AEs showed a consistent upward trend throughout the study period. Conclusion This real-world data analysis provides insights into the distribution of major complications associated with ICL implantation in clinical practice. Comprehensive identification and reporting of rare adverse outcomes may help surgeons broaden their perspectives, enhance surgical preparedness, and provide more personalized and informed preoperative counseling.


  • Open Access

    Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database

    by Qing Chen, Haijing Yan, Letong Chen, Limei Wang, Qinxiang Zheng, Yueping Ren

    Purpose: Implantable Collamer Lens (ICL) implantation is rising globally, yet real-world studies on adverse events (AEs) remain scarce. This study analyses ICL-related complications using the MAUDE database.Methods: Data on ICL-related AEs were extracted from the MAUDE database. Cases were categorized into spherical and toric ICLs based on lens diopter. Descriptive statistics summarized device-related issues and complications, and Cramér’s V assessed their associations. Management strategies and resolution rates for common complications were also evaluated.Results: Among 25,001 ICL-related AEs, 43.8% involved spherical ICLs and 56.2% toric ICLs. Common device-related issues included “Shape and/or size problems” (nearly half of annual AEs) and “Off-label use” (around 20%, rising since 2019 and stabilizing). “Operation and control issues” declined steadily since 2019, stabilizing below 3%. Spherical ICL cases with “Activation, positioning, or separation problems” dropped below 1% post-2019, while toric cases remained at 6.9–9.0%. The top three complications—"Vision issues,” “Intraocular pressure issues” and “Lens-related issues”—were most frequent, with “No patient impact” in most cases. Moderate correlations were found between complications and ICL-related AEs (p = 9.999 × 10−5, Cramér’s V: 0.47 for spherical, 0.45 for toric). Management strategies, including lens exchange and lens extraction followed by surgery, demonstrated high resolution rates.Conclusion: While ICL implantation is generally safe, concerns about inappropriate sizing and off-label use persist. This study suggests that improving lens sizing accuracy and adhering to guidelines may reduce AEs.


  • Incidence of the Stevens‐Johnson syndrome spectrum and its patterns in urban China

    by Chaiquan Li, Mali Dai, Qinyi Gu, Ke Lu, Chaoxiang Ge, Xiaofei Liu, Zhiming Li, Jingying Wang, Jinxi Wang, Chen Wei, et al.

    Stevens‐Johnson syndrome (SJS) spectrum is a series of rare, but life‐threatening mucocutaneous hypersensitivity reactions. However, the epidemiological evidence of it is limited, especially in developing countries. The shape associations with age and its seasonal pattern are still uncertain. Therefore, this study aimed to describe the nationwide incidence of SJS spectrum, its associations with age and season, and its subsequent diagnosed diseases across urban China. By using national health insurance datasets from 2013 to 2017, this retrospective cohort study estimated the incidence of SJS spectrum and its associations in 23 Chinese provinces. SJS spectrum was defined to include SJS and/or toxic epidermal necrolysis (ICD‐10 code: L51.1–2). First, age‐specific incidence rates were estimated in each province and then pooled using a random‐effects model. Relative risks (RR) of SJS spectrum in different seasons were estimated by Poisson regression. Diseases diagnosed within 6 months following SJS occurrence were described. In total, 9308 patients were identified (50.17% women, median age 45). The average standardized incidence rate of SJS spectrum was 3.43 (95% confidence interval [CI] 3.04–3.84) per million person‐years, which increased by 0.57 (95% CI 0.29–0.84) per million person‐years. Incidence rates were significantly higher among children age p = 0.0036) and adults age ≥ 40 (5.50, 95% CI 4.35–6.78, p = 0.00085) than the group aged 10–40 years (3.12, 95% CI 2.29–4.07). The risk of SJS spectrum was highest in summer (vs autumn: RR = 1.83, 95% CI 1.72–1.93). The most frequently diagnosed disease within 6 months after the onset of SJS was respiratory disease (43.8%). In conclusion, this study provides evidence on the epidemiology of SJS spectrum in developing countries and supports the two‐peak distribution of its incidence across age. Its high occurrence in summer needs further confirmation.


  • A promising strategy for ocular noninvasive protein delivery: The case in treating corneal neovascularization

    by Bangxun Mao, Bojiao Tang, Songping Yu, Jia Ying, Jing Wu, Lina Lan, Yanfang Wang, Xingjie Zan, Qinxiang Zheng, Jun Li


  • Open Access

    HMGB1 Promotes Lysosome-Dependent Cell Death Induced Via Dry Eye by Disrupting Lysosomal Homeostasis

    by Xiaojuan Hu, Jiayao Feng, Chengjie Pan, Zhenzhen Sun, Jiechen Liu, Shuang Xie, Decheng Xiao, Xiaoyin Ma, Qinxiang Zheng, Wei Chen

    Hypertonic stress can induce apoptosis, inflammation, and dry eye disease (DED) through the upregulation of HMGB1 expression. However, its role in mediating and maintaining lysosomal homeostasis and suppressing DED development in living and in vitro models is unclear. Immunofluorescence, nucleoplasmic separation, and electron microscopic analysis were used to compare the effects of hypertonic stress on lysosomal function, nuclear HGMB1 expression, and lysosomal localization in three different dry eye models. The live model was established by the subcutaneous injection of scopolamine (SCOP) into C57BL/6J female mice, and the in vitro model used human corneal epithelial cell (HCEC) cultures that were maintained at a hyperosmotic level of 450 milliosmolar (mOsm). RNAi technology was used to knockdown HMGB1 expression levels, altering hyperosmotic stress-induced changes in survival and autophagy of corneal epithelial cells in vitro. Lysosomal protease inhibitors were applied to suppress the increase of corneal tissue inflammation in the dry eye mouse model. This hypertrophic stress upregulated karyoplasmic HMGB1 expression in HCECs. This change disrupted lysosomal structural and functional integrity, which facilitated the release of HMGB1 into the cytoplasm. SiRNAs downregulated HMGB1 expression levels and reversed increases in HMGB1 transfer from the nucleus to the cytoplasm and lysosomal alkalinizing function. These changes promoted increases in cathepsin leakage from lysosomes and increased mouse corneal epithelial apoptosis, whereas autophagy decreased. In a mouse model, administration of a cathepsin inhibitor reduced both ocular inflammation and other aspects of dry eye symptomology. Hyperosmotic-induced HMGB1 upregulation and increased HMGB1 transfer into the cytoplasm from the nucleus underlie the loss of lysosomal membrane integrity, which increases both cathepsin release and corneal epithelial apoptosis. HMGB1 downregulation instead ameliorated these pathogenic responses.